Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ezetimibe/simvastatin vs high-dose simvastatin on postprandial endothelial function in metabolic syndrome
2008-003908-61Phase 4Completed
- Sponsor
- University Medical Center Utrecht
- Start
- Nov 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial of ezetimibe and simvastatin in cardiometabolic risk (CMR) (2 arms), sponsored by University Medical Center Utrecht. Primary endpoints: Postprandial endothelial function by brachial artery FMD and Postprandial endothelial function by ENDOPAT. Started Nov 2008; status: completed.
02
Drugs
ezetimibesimvastatin
03
Conditions
cardiometabolic risk (CMR)
Beyond the preview
Go deeper on 2008-003908-61.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-003908-61.